The 8 best cooling pillows we tested are game-changers for hot sleepers
If you're in search of the best cooling pillow, you're likely familiar with the nightly struggle of overheating and flipping all night long.
Studies show that temperature regulation is crucial to restful sleep, so it's essential to consider materials that provide temperature control, moisture wicking, and comfort that supports your neck.
We have tested many pillows, cooling sheets, and even top sleeping products, so when we say we've seen it all, we really have, and we are testing every day.
Best Cooling Pillow Overall: Coop Sleep Goods Eden Pillow
COOP
Pros: Fully adjustable fill
Machine-washable cover
Hypoallergenic and CertiPUR-US certified
Best cooling pillow for night sweats
Cons: May need fluffing
Slight off-gassing on first use
Great for hot sleepers of all positions. The gel memory foam of the Coop Sleep Goods Eden Pillow regulates heat, while the bamboo cover adds breathability. Its adjustable fill lets you fine-tune the loft and firmness for your sleep position, while the gel-infused foam works to dissipate heat throughout the night.
Fill type: Hypoallergenic, non-toxic blend of memory foam and microfiber | Firmness level: Medium-soft to medium | Cover material: 100% polyester
Best Down Alternative Cooling Pillow: Cozy Earth Bamboo Down Alternative Pillow
Cozy Earth
Pros: Down-alternative (more eco-conscious)
Bamboo has naturally temperature-regulating properties to help sleepers stay cool
Cons: More expensive due to the pricey material and high-quality
New York Post Review: 'Most of us who cherish good sleep are well acquainted with the Cozy Earth brand. The Post Wanted team swears by their cooling sheets, fluffy duvets, and sleek pajama sets, but the single item I can't sleep without is easily the Bamboo Down Alternative Pillow. In my experience, this is about as close as true Down you can get, without sacrificing any real feathers.
The hypothermic combination of temperature-regulating bamboo and recycled polyester offers that cooling, sinkable feeling that cradles your head and neck, no matter what position you find yourself in (ideal for tossers and turners).
The viscose also wicks away moisture, keeping you cool year-round. I'm not overly sensitive to heat, but I've noticed such a difference in the amount of airflow I get with this pillow. It's the air around you, not just the material beneath you, that feels much more breathable. I'm betting it's the only reason I can survive this year's heat wave, without waking up in a pile of sweat.' – Miska Salemann, commerce reporter
Miska Saleman
Fill type: Recycled polyester down-alternative blend | Firmness level: Medium-soft | Cover material: Viscose from bamboo
Best Cooling Neck Pillow for Side Sleeper: Eli & Elm Best Pillow for Neck Pain
Pros: Shredded latex fills help with airflow and keep temperatures cooler around you
Breathable cotton cover is suitable for most skin textures/types (and easy to wash)
Best cooling pregnancy pillow
Cons: The design is not ideal if you're not a side-sleeper
New York Post Review: 'I was forced to learn how to side-sleep during pregnancy, and one of the best ways to get myself properly situated was investing in a side-sleeping pillow. What I wish I had found was one that also offered a cooling effect, because, like many pregnant women, I was hot, bothered, and hardly sleeping most of the third trimester. I've since come to discover the Eli & Elm Cotton Side-sleeper Pillow, and my only regret is that I hadn't invested in one earlier.
The design is carefully shaped to support the head and neck and keep you in the proper form while you sleep, and it's also encased with a breathable cotton cover, with cooling gels, and a proprietary shredded latex fill that offers ideal airflow and keeps temperatures lower through the night. Here's the deal: If you're not a side-sleeper, you may have trouble with the way this pillow positions you. But if you are one, you're probably missing out. It's soft, supportive, yet cooling at the same time. Kind of dream if you're pregnant, suffer from back pain, or need to be the little spoon.' — Salemann
Fill type: 75% latex & 25% polyester fiber | Firmness level: Medium | Cover material: smooth cotton, blended with ultra fine polyester and spandex
Best Adaptive Foam Cooling Pillow: Sleep Number True Temp Pillow
Sleep Number
Pros: Active-particle technology attracts and removes moisture vapor to reduce humidity
Molds to your head and neck shape overnight
Cons: The pillow cover is on the thicker side, and the bubbly texture may not be ideal for people who prefer a flatter surface
New York Post Review: 'On first look, I wondered if the True Temp Adapt's unique design would help keep me cool at night, or if it was just a piece of bubbly modern decor (that cover definitely has a different look than some others I've slept on). But, since I've started sleeping on it, the first point has proven true. Sleep Number's cooling pillow features adaptive foam contours that mold to the head and neck and enhance airflow. Unique active-particle technology traps heat and humidity, and a cool-to-the-touch cover slips off easily, as pictured. My sleep hasn't been affected by NYC's heatwave (thus far), so I'd say it's doing its job. If you're not a fan of the thicker, textured cover, you can easily replace it with another pillow case.' — Salemann
Fill type: 46% polyethylene, 31% 37.5 polyester, 23% polyester, filled with 80% polyester, 20% 37.5 polyester| Firmness level: Medium | Cover material: Cool-touch hypoallergenic fabric
Miska Saleman
Best Bamboo Cooling Pillow: Cariloha Retreat Bamboo Pillow
Cariloha
Pros: Naturally moisture-wicking
Hypoallergenic and eco-friendly
Excellent airflow
Cons: Slightly firm for stomach sleepers
This eco-friendly option uses bamboo charcoal-infused memory foam to combat heat and odors while providing steady support. The bamboo-derived cover is naturally breathable and moisture-wicking, which helps regulate body temperature. It's ideal for sleepers who want a sustainable and hypoallergenic alternative.
Fill type: Bamboo viscose blend | Firmness level: Medium | Cover material: Bamboo viscose blend
Best Budget Cooling Pillow: Beckham Hotel Collection Gel Pillow
Beckham Hotel Collection
Pros: Budget-friendly (set of 2)
Soft and plush
Cooling cotton cover
Cons: Less contouring support
This bestselling set of two pillows offers plush comfort and effective cooling without the premium price tag. Filled with a soft gel down alternative and encased in a breathable cotton shell, the Beckham Hotel Collection pillows are a go-to choice for budget-conscious shoppers who want that luxury hotel feel without breaking the bank.
Fill type: 100% polyester fiber | Firmness level: Medium | Cover material: 100% cotton
Best Memory Foam Cooling Pillow: TEMPUR-Cloud Breeze Dual Cooling Pillow
Amazon
Pros: Dual gel layers on both sides
Excellent contouring
Trusted Tempur-Pedic quality
Great firm cooling pillow for support
Cons: Higher price point
The TEMPUR-Cloud Breeze is a splurge-worthy option that combines Tempur-Pedic's signature contouring foam with dual gel layers to keep both sides of the pillow cool. It offers excellent support for side and back sleepers and holds its shape exceptionally well. If you want luxurious comfort and long-lasting cooling, this one is hard to beat.
Fill type: TEMPUR memory foam with cooling gel layers | Firmness level: Medium-firm | Cover material: N/A
Best Cooling Pillow for Back/Stomach Sleepers: Casper Hybrid Pillow with Snow Technology
Casper
Pros: Breathable mesh gusset
Doesn't trap heat
Plush but supportive
Cons: May feel too soft for side sleepers
Casper's Snow Technology adds an instant cooling feel the moment your head hits the pillow, while the perforated foam core enhances breathability. The soft yet supportive design is best suited for back and stomach sleepers who want plush comfort without overheating. Bonus: it bounces back quickly and keeps its shape well.
Fill type: AirScape perforated foam + fiber | Firmness level: Soft to medium | Cover material: Cool-to-the-touch knit
How We Tested
We read hundreds of customer reviews, consulted third-party ratings, and personally tested two top-rated cooling pillows over several nights of sleep. Our goal was to assess how well they delivered on comfort, cooling, and support for different sleep styles.
We evaluated the following:
Cooling ability : Was it actually cool? If so, how long did it stay that way?
: Was it actually cool? If so, how long did it stay that way? Support & comfort : We reviewed whether the pillow provided a stabilized cushion throughout multiple sleeps.
: We reviewed whether the pillow provided a stabilized cushion throughout multiple sleeps. Material quality : We looked at each pillow's materials and gave extra points to those that had cooling technologies and materials known to fight heat.
: We looked at each pillow's materials and gave extra points to those that had cooling technologies and materials known to fight heat. Sleep position adaptability : For each pillow, we questioned who it was best for and whether it could work for various types of sleepers.
: For each pillow, we questioned who it was best for and whether it could work for various types of sleepers. Price point: We looked at all of the above criteria and measured them against the asking price of each pillow. Pricier pillows that had minimal cooling design features but a higher price were quickly removed from our final edit in favor of options that provided more bells and whistles for the same price.
What is the best material for a pillow to stay cool?
Gel-infused shredded memory foam is a popular choice due to its combination of breathability and support, especially for those who suffer from night sweats. Latex and microfiber clusters also do well. Look for fillings labeled with phase-change materials. Memory foam infused with gel or graphite tends to perform best for both cooling and support. Latex is another excellent choice — it's naturally breathable and resistant to heat retention. If softness is key, down-alternative fills with moisture-wicking covers (like bamboo or Tencel) offer airy comfort.
What is the coolest pillow filling?
Gel-infused shredded memory foam is a popular choice due to its combination of breathability and support. Latex and microfiber clusters also do well. Look for fillings labeled with phase-change materials or proprietary blends from brands like Tempur-Pedic, Columbia, and Sealy.
For over 200 years, the New York Post has been America's go-to source for bold news, engaging stories, in-depth reporting, and now, insightful shopping guidance. We're not just thorough reporters – we sift through mountains of information, test and compare products, and consult experts on any topics we aren't already schooled specialists in to deliver useful, realistic product recommendations based on our extensive and hands-on analysis. Here at The Post, we're known for being brutally honest – we clearly label partnership content, and whether we receive anything from affiliate links, so you always know where we stand. We routinely update content to reflect current research and expert advice, provide context (and wit) and ensure our links work. Please note that deals can expire, and all prices are subject to change.
Looking for a headline-worthy haul? Keep shopping Post Wanted.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients
Astria Therapeutics Inc. (NASDAQ:ATXS) is one of the stocks under $10 to buy now. Earlier on June 13, Astria Therapeutics announced positive initial results from the ALPHA-SOLAR long-term open-label trial of navenibart (STAR-0215) in hereditary angioedema/HAE patients. These findings were presented at the European Academy of Allergy and Clinical Immunology/EAACI Annual Congress. The trial showed an overall reduction in the monthly HAE attack rate, with a 92% mean and 97% median reduction. These results support the potential for every three-month and every six-month dosing regimens for navenibart, as well as its favorable safety and tolerability profile. These initial results from ALPHA-SOLAR are consistent with the 'best-in-class' profile observed in the earlier ALPHA-STAR Phase 1b/2 trial. A closeup of pills in a pharmacy, representing the high quality medications of the company. The ALPHA-SOLAR trial is a long-term, open-label study designed to assess the safety and efficacy of navenibart in adults with HAE Type 1 or 2. All 16 target enrollment participants from the Phase 1b/2 ALPHA-STAR trial opted to enroll in ALPHA-SOLAR. Patients from ALPHA-STAR Cohorts 1 and 2 joined Arm A, while Cohort 3 patients joined Arm B. Astria Therapeutics Inc. (NASDAQ:ATXS) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for allergic and immunological diseases in the US. While we acknowledge the potential of ATXS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
3 hours ago
- Yahoo
A single injection for newborns could protect them against HIV for years, study suggests
A single injection at birth could shield children from HIV for years, a study has suggested. The study is one of the first to show that the first weeks of life offer a critical window where the immune system is naturally more tolerant, meaning it is the optimal time to deliver gene therapies that would otherwise be rejected at older ages. Researchers hope the gene therapy jab could be used in the future to fight against paediatric infections in high-risk areas. 'Nearly 300 children are infected with HIV each day,' said first author Amir Ardeshir, associate professor of microbiology and immunology at the Tulane National Primate Research Center in the US. 'This approach could help protect newborns in high-risk areas during the most vulnerable period of their lives.' The study, published in the journal Nature, created a gene therapy that programs cells to produce HIV-fighting antibodies. An animal study that tested the injection on non-human primates found it protected them from infection for at least three years without the need for a booster shot. But this was only if the injection was administered in the first month of life. In comparison, those that received the gene therapy between eight and 12 weeks after birth did not tolerate the treatment, study authors explain. 'This is a one-and-done treatment that fits the critical time when these mothers with HIV in resource-limited areas are most likely to see a doctor,' Dr Ardeshir said. 'As long as the treatment is delivered close to birth, the baby's immune system will accept it and believe it's part of itself.' Globally, an estimated 1.3 million women and girls living with HIV become pregnant every year, according to the World Health Organization (WHO). But if they do not receive medication, the rate of transmission of HIV from the mother to her child either during pregnancy, labour, delivery or breastfeeding ranges between 15 per cent and 45 per cent, according to WHO data. Although antiviral treatments can suppress the virus and limit transmission, adherence to treatment and doctor visits decline after childbirth, particularly in areas with limited access to healthcare, the study authors noted. This gene therapy uses a harmless virus that can deliver genetic code to cells, but is different to a vaccine. This virus was injected into muscle cells and delivered instructions to produce antibodies that are capable of neutralising multiple strains of HIV. Researchers explained that previous studies have found repeated infusions of the injection are needed for it to work. But by injecting it into muscle cells, researchers say they become 'micro-factories that just keep producing these antibodies'. Newborns showed greater tolerance to the jab, which prevented infection during breastfeeding. However, older infants and juveniles were more likely to have produced anti-drug antibodies that shut down the treatment. In addition, exposing a foetus to the antibodies from the gene therapy before birth helps older infants accept the therapy. However, because it has only been tested on animals, researchers still do not know if it will work on human children. If successful, this treatment could dramatically reduce mother-to-child HIV transmission rates in high-risk regions such as sub-Saharan Africa, where 90 per cent of paediatric HIV cases can be found. 'Nothing like this was possible to achieve even 10 years ago,' Dr Ardeshir said. 'This was a huge result, and now we have all the ingredients to take on HIV.'
Yahoo
4 hours ago
- Yahoo
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5 atherosclerotic cardiovascular disease (ASCVD) patients do not reach guideline-recommended LDL-C target, reinforcing urgent need for more aggressive LDL-C lowering2-5 Twice-yearly Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment EAST HANOVER, N.J., July 31, 2025 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia1. The FDA proactively requested the label update based on the robust LDL-C lowering data for PCSK9-targeting therapies. "This first-line label update reinforces Leqvio's proven ability to effectively lower LDL-C, a critical risk factor for heart disease," said Victor Bultó, President, US, Novartis. "With this new indication enabling Leqvio's use as monotherapy along with diet and exercise, we now have the potential to help even more patients achieve their LDL-C lowering goals earlier in their treatment journey." With its twice-yearly, health care provider-administered dosing, Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment. This is a critical unmet need, as up to 80% of ASCVD patients in the US struggle to reach the LDL-C guideline-recommended target of <70 mg/dL2-5. This need is heightened by the latest 2025 ACC/AHA Joint Committee Clinical Practice Guideline for the Management of Patients with Acute Coronary Syndromes, which recommends more aggressive treatment to achieve LDL-C targets6. The updated label removes the requirement for Leqvio to be used on top of or in combination with statin therapy1. Other updates include revising "primary hyperlipidemia" to the more specific term of "hypercholesterolemia" throughout the label, to more accurately focus on LDL-C reduction1. *After an initial dose and another at three months. About LeqvioLeqvio is an injectable prescription medicine indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics. Important Safety InformationDo not use if you have had an allergic reaction to Leqvio or any of its ingredients. The most common side effects of Leqvio were injection site reaction (including pain, redness, and rash), arthralgia (joint pain), bronchitis (chest cold). These are not all the possible side effects of Leqvio. Ask your health care provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Please click here for Leqvio full Prescribing Information. About Atherosclerotic Cardiovascular Disease (ASCVD)Cardiovascular disease (CVD) affects hundreds of millions of people and claims more lives globally than cancer, chronic lung disease and diabetes combined7. Around 80% of premature cardiovascular deaths can be prevented by addressing factors that cause or worsen accounts for 85% of all CV deaths5,9-11. Its burden in the US is greater than that of any other chronic diseases5,9-11. ASCVD is caused by the development and growth of plaques in the inner lining of the arteries12. The atherosclerotic plaque is mainly composed of low-density lipoprotein cholesterol (LDL-C) that accumulates over time13. Cumulative exposure to LDL-C can increase one's risk of cardiovascular events such as a heart attack or stroke12,13. About Novartis in Cardiovascular DiseaseAt Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We're proud of the positive impact we've made over the past 40 years and remain dedicated to tackling the most challenging problems in CVD. Through cutting-edge science and technology, we are focusing on areas of high unmet need, including scaling our xRNA platform across multiple risk factors and pioneering breakthroughs for genetically driven CVD risk factors and common heart conditions, including atrial fibrillation. We also work with patients, healthcare professionals, and organizations around the world to improve CV care beyond medicine alone. Together, we can help people with CVD enjoy longer, healthier lives and more time with their loved ones. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About NovartisNovartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn US, X/Twitter US and Instagram. References Leqvio. Prescribing information. Novartis Pharmaceuticals Corp Cannon CP, de Lemos JA, Rosenson RS, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060-1068. doi:10.1001/jamacardio.2021.1810 Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/ Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1016/ Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;85(22):2135-2237. doi:10.1016/ American Heart Association. More than half of U.S. adults don't know heart disease is leading cause of death, despite 100-year reign. Published January 24, 2024. Accessed July 25, 2025. World Heart Federation. World Heart Report 2023: confronting the world's number one killer. Published May 20, 2023. Accessed July 25, 2025. World Health Organization. Cardiovascular diseases (CVDs). Published June 11, 2021. Accessed July 25, 2025. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220. doi:10.1161/CIR.0b013e31823ac046 Kim H, Kim S, Han S, et al. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. BMC Public Health. 2019;19(1):1112. doi:10.1186/s12889-019-7439-0 Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):161-172. doi:10.1016/ Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(10):1141-1156. doi:10.1016/ ### Novartis Media Relations E-mail: Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: original content: SOURCE Novartis Pharmaceuticals Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
